We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+20.56%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$84.3M
AUM Growth
+$12.6M
(+18%)
Cap. Flow
+$1.91M
Cap. Flow
% of AUM
2.26%
Top 10 Holdings %
Top 10 Hldgs %
61.92%
Holding
37
New
10
Increased
7
Reduced
11
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$5.48M |
| 2 |
Gilead Sciences
GILD
|
+$3.8M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$3.43M |
| 4 |
Acadia Healthcare
ACHC
|
+$3.14M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HMSY
HMS Holdings Corp.
HMSY
|
+$4.83M |
| 2 |
Eli Lilly
LLY
|
+$4.51M |
| 3 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
+$2.97M |
| 4 |
GSK
GSK
|
+$1.97M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$1.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.41% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATRS
26
DELISTED
Antares Pharma, Inc.
ATRS
| $643K | 0.76% |
+199,655
| New | +$566K |
|
27
Regenxbio
RGNX
$638M
| $275K | 0.33% |
13,906
+1,508
| +12% | +$29.2K |
|
|
OXFD
28
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $273K | 0.32% |
+16,212
| New | +$242K |
|
29
AstraZeneca
AZN
$245B
| – | – |
-12,405
| Closed | -$773K |
|
30
Biogen
BIIB
$29.8B
| – | – |
-3,073
| Closed | -$840K |
|
31
Cardinal Health
CAH
$55.2B
| – | – |
-10,049
| Closed | -$819K |
|
32
Incyte
INCY
$24B
| – | – |
-12,931
| Closed | -$1.73M |
|
|
33
Eli Lilly
LLY
$1,000B
| – | – |
-53,583
| Closed | -$4.51M |
|
34
Puma Biotechnology
PBYI
$391M
| – | – |
-42,524
| Closed | -$1.58M |
|
35
Syndax Pharmaceuticals
SNDX
$1.7B
| – | – |
-60,087
| Closed | -$824K |
|
|
HMSY
36
DELISTED
HMS Holdings Corp.
HMSY
| – | – |
-237,802
| Closed | -$4.83M |
|
|
KERX
37
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-68,381
| Closed | -$421K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Asymmetry Capital Management held 37 positions worth $84.3M, up 18% from $71.7M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Asymmetry Capital Management's Q2 2017 filing shows 10 new, 7 increased, 11 reduced and 9 closed positions. Its largest new stake was Medtronic: 65,036 shares worth $5.77M. The largest sale was HMS Holdings Corp., an estimated $4.83M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier, followed by Industrials.
- Asymmetry Capital Management's largest Q2 2017 buy was Medtronic: 65,036 shares worth $5.77M.
- Asymmetry Capital Management added most to Acadia Healthcare in Q2 2017, an estimated $3.14M increase.
- Asymmetry Capital Management's biggest Q2 2017 reduction was Synergy Pharmaceuticals, Inc Common Stock, cutting an estimated $2.97M.
- Asymmetry Capital Management fully exited HMS Holdings Corp. in Q2 2017, selling an estimated $4.83M.
- Asymmetry Capital Management's ten largest holdings make up 62% of its $84.3M portfolio in Q2 2017.
- Asymmetry Capital Management opened 10 new positions and closed 9 in Q2 2017.
- Asymmetry Capital Management's portfolio value rose 18% quarter-over-quarter to $84.3M.
Based on Asymmetry Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.